Feature | August 27, 2012

Manhattan Isotope Starts Formal Process to Produce Sr-82

August 27, 2012 — Positron Corp., a molecular imaging healthcare company, announced the submission of a drug master file (DMF) with the U.S. Food and Drug Administration (FDA) for the production of active pharmaceutical ingredient (API)-grade strontium-82 (Sr-82) through its wholly owned subsidiary, Manhattan Isotope Technology LLC (MIT). This will offer a second source for the nuclear myocardial perfusion cardiac imaging agent.

A DMF is a document submitted to the FDA that contains complete information on an API or finished drug dosage form. The DMF contains factual and complete information on a drug product's chemistry, manufacturer, stability, purity, impurity profile, packaging and the cGMP status of any human drug product. The main objective of the DMF is to support regulatory requirements and to prove the quality, safety and efficacy of the medicinal product.

Manhattan Isotope’s DMF submission initiates the protocol, procedures and compliance required to produce Sr-82 for radiopharmaceutical applications, specifically for commercial use in Sr-82/Rubidium (Rb)-82 generators. Sr-82/Rb-82 generator manufacturers may now qualify MIT as a supply source and vendor for API grade Sr-82. 

Manhattan Isotope’s DMF positions the company as the only commercial entity in the United States in the Sr-82 processing and production arena. Currently, the U.S. Department of Energy (DOE) is the only domestic supplier for many of the more than 300 different isotopes, which are critical in medical, commercial, research and national security applications. Recent shortages have emphasized the importance of managing the demand for critical isotopes.

“Our submission of the DMF is a very significant milestone, as it signifies Positron’s evolution towards a vertically integrated nuclear medicine healthcare company," said Jason Kitten, president of MIT. "Positron, through MIT, is the first private entity to demonstrate the expertise and ability to enter the market as a processor and supplier of API-grade strontium-82. Proficiencies in this segment are key to our end-to-end solution strategy. Positron’s ability to supply strontium and support production needs will not only stabilize the source supply of strontium-82, but will also lend growth to and strengthen the cardiac positron emission tomography (PET) market as a whole.”

For more information: www.positron.com

Related Content

Siemens Healthineers, Symbia Intevo SPECT/CT system, xSPECT Quant, RSNA 2016
Technology | SPECT-CT| October 18, 2016
At the 2016 annual meeting of the Radiological Society of North America (RSNA 2016), Siemens Healthineers will showcase...
Lantheus, flurpiridaz F-18, myocardial perfusion imaging, MPI, cardiac stress testing, ASNC 2016
News | Radiopharmaceuticals and Tracers| October 17, 2016
Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3 study of flurpiridaz F...
GE Healthcare, Discovery MI PET/CT system, FDA clearance, RSNA 2016
Technology | PET-CT| October 05, 2016
GE Healthcare recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Discovery MI digital...
ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging| September 01, 2016
September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...
UltraSPECT, Xpress3.Cardiac, nuclear imaging, RWJPE, New Jersey, Robert Wood Johnson Physician Enterprise
News | SPECT Imaging| July 25, 2016
UltraSPECT Inc. announced recently that Robert Wood Johnson Physician Enterprise (RWJPE), a multi-specialty, community-...
ASNC, SNMMI, PET standard, Pet cardiac imaging, PET nuclear imaging, perfusion imaging

An example of a cardiac PET-CT imaging, should a color coded image of the left ventricle to help assess myocardial perfusion to detect ischemia using a Siemens scanner.

News | Nuclear Imaging| July 19, 2016
Cell>Point, license agreement, China, United Eastern Pharmaceutical, Oncardia imaging agent
News | Radiopharmaceuticals and Tracers| July 07, 2016
July 7, 2016 — Cell>Point announced in mid-June it has entered into an...
SNMMI, appropriate use criteria, AUC, PAMA, qualified provider-led entity, PLE
News | Clinical Decision Support| June 27, 2016
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has been named a qualified provider-led entity (PLE)...
Philips, SNMMI 2016, Vereos digital PET/CT, time-of-flight, IntelliSpace 8.0, nuclear imaging
News | Nuclear Imaging| June 14, 2016
Philips announced it would be showcasing a variety of nuclear imaging solutions at the Society of Nuclear Medicine and...
Siemens Healthineers, SNMMI '16, molecular imaging, syngo.via, Biograph Horizon PET/CT, mobile configuration
Technology | Nuclear Imaging| June 09, 2016
At the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Siemens Healthineers will...
Overlay Init